Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE Elevated baseline circulating adiponectin level is possibly associated with an increased risk of all-cause mortality and the combined endpoints of death/readmission in patients with heart failure. 31314851 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Clinical and Humoral Determinants of Congestion in Heart Failure: Potential Role of Adiponectin. 31553971 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE The levels of NGAL and adiponectin were higher in LVAD recipients and patients with heart failure as compared with healthy controls. 30699407 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE However, plasma levels of adiponectin have been shown to inversely correlate with muscle mass and strength in elderly people especially with chronic heart failure (CHF). 30626897 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE <b>Methods:</b> Adiponectin circulating levels were determined by ELISA at discharge in patients admitted for <i>de novo</i> HF (n=74). 29559829 2018
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 GeneticVariation disease BEFREE Neither serum adiponectin nor ADIPOQ variants predicted HF. 29969725 2018
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 GeneticVariation disease BEFREE Patients with the highest baseline adiponectin concentration (quartile [Q]4) were at significantly higher risk of death from a CV event (8.4% vs 1.7%; P < .0001), hospitalization for heart failure (HF; 7.5% vs 1.7%; P < .0001), and all-cause mortality (10.8% vs 2.4%; P < .0001) compared with those in Q1. 28195387 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Our study shows that fenofibrate may protect against ET-1-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiac hypertrophy and heart failure. 27629528 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE The aim of the study was to evaluate the relationship between body mass index (BMI), leptin and adiponectin concentrations and prognosis in patients with heart failure due to non ischeamic dilated cardiomyopathy (NIDCM). 28255978 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE TT and eFT were independently determined by age, total fat mass and adiponectin levels in elderly men with HF (p < 0.05 for all). 28696825 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE When adiponectin is used in conjunction with NT-proBNP in chronic HF, the prognostic value may be better than if each biomarker is used separately. 28344417 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE The Role of Serum Adiponectin for Outcome Prediction in Patients with Dilated Cardiomyopathy and Advanced Heart Failure. 29318144 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Previously, we demonstrated a functional skeletal muscle adiponectin resistance in HF patients with reduced left ventricular ejection fraction (HFrEF). 26921438 2016
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Therapeutic disease CTD_human Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice. 26670611 2016
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease CTD_human Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice. 26670611 2016
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE Expression of adiponectin and adiponectin receptors (ADIPOR1 and ADIPOR2) was studied by qPCR and immunohistochemistry in myocardial tissues of patients with end-stage CHF and control subjects. 24239242 2014
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Plasma BNP was the strongest predictor of circulating adiponectin and its release from all adipose tissue depots in patients with coronary artery bypass grafting, even in the absence of HF. 25060790 2014
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE The aim of our study was to assess the relationship between p53 and adiponectin mRNA in epicardial adipose tissue (EAT) and subcutaneous adipose tissue (SAT) in patients with heart failure and its sympathetic regulation. 24117366 2014
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Therefore, we aimed to investigate whether adiponectin would have a beneficial effect in iron-induced chronic heart failure and to elucidate its regulation in cardiomyocytes. 23723143 2013
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE Cox proportional hazards models adjusting for covariates in stages revealed that only baseline EAT adiponectin levels and heart failure could predict CV events. 22974530 2012
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Mean (SD) age was 71.6 (9.6) years.Patients who met Adult Treatment Panel III MS criteria (n=29) presented lower plasma adiponectin concentrations (11.2 (7.4) vs. 19.6 (8.4) mg/l, P=0.004), lower EAT adiponectin mRNA (12.7 (3.0) vs. 15.1 (3.7) a.u., P=0.029) and similar SAT adiponectin mRNA levels (13.7 (4.2) vs. 15.6 (5.7) a.u., P=0.25) than those without MS. After adjusting for age, sex, CAD and heart failure, the association with MS remained statistically significant for plasma adiponectin (OR 0.862 (0.762-0.974)), was of borderline significance for EAT adiponectin mRNA (OR 0.796 (0.630-1.005)) and not significant for SAT adiponectin mRNA (OR 0.958 (0.818-1.122)). 21330150 2011
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Plasma adiponectin was measured at entry and after 3 months in approximately 1200 patients with CHF enrolled in the GISSI-HF trial. 21623778 2011
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 AlteredExpression disease BEFREE Adiponectin expression in the skeletal muscle of patients with CHF was 5-fold higher than in healthy subjects (P<0.001), whereas AdipoR1 was downregulated (P=0.005). 20103776 2010
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Biomarker disease BEFREE Natriuretic peptides enhance adiponectin production by human adipocytes in vitro and even in patients with CHF, which might have a beneficial effect on cardiomyocytes in patients receiving recombinant natriuretic peptide therapy for heart failure. 19477358 2009
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.400 Therapeutic disease CTD_human Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. 19367012 2009